Make Concerted Efforts and Struggle Together with the Original Aspiration Unchanged - XNW5004 has successfully completed a Phase I clinical trial and is undergoing a Phase II clinical trial

XNW5004 is a Best-in-Class epigenetic EZH2 inhibitor with independent intellectual property rights owned by Suzhou Evopoint Biosciences Co., Ltd. (hereinafter referred to as Evopoint). It has a huge but unmet clinical demand at present.

In Phase I trial, XNW5004 showed good anti-tumor effect in all dose groups, and the optimal effect was complete remission (CR). Meanwhile, XNW5004 indicated a good safety in all the subjects. Relevant data of Phase I trial will be published at an international conference.

In addition, XNW5004 will be involved in the R&D stage of solid tumors in the near future, and will be studied clinically in combination with multiple drugs on multiple solid tumor indications.